Please assess the completion status of the following clinical trial:

Trial Title: Amitriptyline in Treating Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 1 Diabetes Mellitus for at least 5 years or more~* Age between 21 to 60 years old~* HbA1c less or equal to 9% with the latest measurement within the last 3 months~* Use of real time Continuous Glucose Monitoring (rtCGM) providing continuous glucose data points for at least 3 months, and at least 80% of CGM readings available over the last 2-week period~* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines~Exclusion Criteria:~* Ongoing or recent history of major depressive disorder, or other ongoing major psychiatric disorders~* History of anti-depressant use within the last three months~* Insulin pump linked to a CGM with programmed automatic insulin adjustment or suspension~* History of advanced cardiac, liver, kidney or neurological disease~* Active malignancy~* Uncontrolled Human Immunodeficiency Virus diseases~* Advanced diabetic retinopathy, neuropathy, or nephropathy~* Frequent acetaminophen use which can disrupt CGM accuracy~* Pregnancy or female of child-bearing potential unable to practice effective contraception during the study period~* Breastfeeding female, or female with prospective plan to initiate breastfeeding~* Ongoing history of alcohol abuse~* Contraindication to amitriptyline use, including hypersensitivity to amitriptyline or any component of the formulation, co-administration with or within 14 days of Monoamine Oxidase Inhibitors and co-administration with cisapride~* Inability to understand or cooperate with study procedures, including taking study drugs and recording hypoglycemic symptoms.~The participants meeting the above criteria will enter Run-in Period. At the Visit 2, the following additional exclusion criteria will be applied before study drug randomization:~* \< 80% of CGM readings available over the last 2-week period~* Time spent in hypoglycemia (i.e., \< 70 mg/dL) for \< 5% over a 2-week period on based on CGM reading.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Amitriptyline (Type: EXPERIMENTAL): Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be initiated on a daily Placebo capsule matching the 25 mg Amitriptyline during the Titration Period. The daily dose will be changed to the Placebo capsule matching the 50 mg Amitriptyline for 8 weeks during the Intervention Period. Finally, the daily dose will be changed back to the Placebo capsule matching the 25 mg Amitriptyline during the two week Taper period.

Based on this trial design, predict the completion outcome and termination type (if applicable).